Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Chen, Jieer Ying et al.|Journal of Clinical Oncology|2021Cited by 417
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III TrialShukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 191
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.Feng Bi, Feng Chen, Shukui Qin et al.|Journal of Clinical Oncology|2020Cited by 39